Gene editing could provide a revolutionary cure for gene-linked diseases. But does it take medicine too far?
Jonathan Kimmelman directs the biomedical ethics unit at McGill University in Montreal, Quebec. His research focuses on the ethical and social implications of human testing for genetic technologies.
Tetsuya Ishii is a professor in the Office of Health and Safety at Hokkaido University in Hokkaido, Japan. He participated in the 2015 international summit on human gene editing.
Hille Haker is the chair of Catholic moral theology at Loyola University Chicago, where she studies human rights, bioethics and feminist ethics. Haker serves as editor of the Values in Bioethics book series and is a member of the European Group on Ethics in Sciences and New Technologies of the European Commission.
Fola Esan is director of the Institute of Genetic Chemistry and Laboratory Medicine in Ibadan, Nigeria. He previously served as director of the National Institute for Medical Research in Lagos, Nigeria.
K. Vijay Raghavan is secretary to the Government of India Ministry of Science and Technology’s Department of Biotechnology and a professor of developmental genetics at the National Centre for Biological Sciences in Bangalore, India. He took part in the first international summit on human gene editing in December 2015.
Ephrat Levy-Lahad teaches medical genetics at the Hebrew University of Jerusalem and directs the Medical Genetics Institute at Shaare Zedek Medical Center. She took part in the International Summit on Human Gene Editing in December 2015.
Annelien Bredenoord is a professor of the ethics of biomedical innovation at the University Medical Center Utrecht in the Netherlands. One of her areas of interest is how to ethically move medical advancements from the research to clinical care stage.
Francoise Baylis is a philosophy and bioethics professor at Dalhousie University in Halifax, Nova Scotia, Canada. She studies women’s reproductive health, new genetic technologies and health care access.